Canaccord lowered the firm’s price target on Kenvue (KVUE) to $24 from $27 and keeps a Buy rating on the shares. The firm said excluding FX headwinds, organic sales were up as management noted that a weaker start to the cough/cold season negatively impacted their pediatric pain business in addition to a disruption with a distribution network in China/ APAC significantly pressuring the Essential Health business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE: